Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals

[1]  Danny Chee Furng Wong,et al.  Impact of dynamic online fed-batch strategies on metabolism, productivity and N-glycosylation quality in CHO cell cultures. , 2005, Biotechnology and bioengineering.

[2]  F. Wurm.  Production of recombinant protein therapeutics in cultivated mammalian cells , 2004, Nature Biotechnology.

[3]  Mohamed Al-Rubeai,et al.  The selection of high-producing cell lines using flow cytometry and cell sorting , 2004, Expert opinion on biological therapy.

[4]  K. Thiel,et al.  Biomanufacturing, from bust to boom...to bubble? , 2004, Nature Biotechnology.

[5]  Zachary Shriver,et al.  Glycomics: a pathway to a class of new and improved therapeutics , 2004, Nature Reviews Drug Discovery.

[6]  Amine Kamen,et al.  Acoustic cell filter: a proven cell retention technology for perfusion of animal cell cultures. , 2004, Biotechnology advances.

[7]  M. Betenbaugh,et al.  Life and death in mammalian cell culture: strategies for apoptosis inhibition. , 2004, Trends in biotechnology.

[8]  Kouhei Tsumoto,et al.  Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. , 2004, Journal of molecular biology.

[9]  A. Pavlou.  Marketspace: The immunotherapies markets, 2003–2008 , 2004 .

[10]  Y. H. Sung,et al.  Yeast hydrolysate as a low-cost additive to serum-free medium for the production of human thrombopoietin in suspension cultures of Chinese hamster ovary cells , 2004, Applied Microbiology and Biotechnology.

[11]  Jaeseung Yoon,et al.  Improved recombinant gene expression in CHO cells using matrix attachment regions. , 2004, Journal of biotechnology.

[12]  A. Dickson,et al.  Molecular definition of predictive indicators of stable protein expression in recombinant NS0 myeloma cells , 2004, Biotechnology and bioengineering.

[13]  Alan T. Bull,et al.  Application of a statistical design to the optimization of culture medium for recombinant interferon-gamma production by Chinese hamster ovary cells , 1992, Applied Microbiology and Biotechnology.

[14]  Sung Hyun Kim,et al.  Effect of Low Culture Temperature on Specific Productivity and Transcription Level of Anti‐4–1BB Antibody in Recombinant Chinese Hamster Ovary Cells , 2008, Biotechnology progress.

[15]  Jolyon Holdstock,et al.  Transgenes encompassing dual-promoter CpG islands from the human TBP and HNRPA2B1 loci are resistant to heterochromatin-mediated silencing. , 2003, Genomics.

[16]  Gary Walsh.  Biopharmaceutical benchmarks—2003 , 2003, Nature Biotechnology.

[17]  B. van den Hazel,et al.  Glycosylation of an N-terminal extension prolongs the half-life and increases the in vivo activity of follicle stimulating hormone. , 2003, The Journal of clinical endocrinology and metabolism.

[18]  Z. Erbayraktar,et al.  Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. Egrie,et al.  Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. , 2003, Experimental hematology.

[20]  K. Shitara,et al.  The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity* , 2003, The Journal of Biological Chemistry.

[21]  D. T. Molowa,et al.  The state of biopharmaceutical manufacturing. , 2003, Biotechnology annual review.

[22]  T. Logtenberg,et al.  High‐Level Expression of Recombinant IgG in the Human Cell Line PER.C6 , 2003, Biotechnology progress.

[23]  Inger Sandlie,et al.  Therapeutic antibodies for human diseases at the dawn of the twenty-first century , 2003, Nature Reviews Drug Discovery.

[24]  L. Presta,et al.  Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity* , 2002, The Journal of Biological Chemistry.

[25]  G. Kretzmer,et al.  Industrial processes with animal cells , 2002, Applied Microbiology and Biotechnology.

[26]  Francesc Gòdia,et al.  The protection of hybridoma cells from apoptosis by caspase inhibition allows culture recovery when exposed to non-inducing conditions. , 2002, Journal of biotechnology.

[27]  Gyun Min Lee,et al.  Response of recombinant Chinese hamster ovary cells to hyperosmotic pressure: effect of Bcl-2 overexpression. , 2002, Journal of biotechnology.

[28]  D. Andersen,et al.  Recombinant protein expression for therapeutic applications. , 2002, Current opinion in biotechnology.

[29]  M. Butler,et al.  The Effect of Cell Culture Parameters on Protein Glycosylation , 2002 .

[30]  L. Castilho,et al.  Cell retention devices for suspended-cell perfusion cultures. , 2002, Advances in biochemical engineering/biotechnology.

[31]  J. Davies,et al.  Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. , 2001, Biotechnology and bioengineering.

[32]  J. Briggs,et al.  Glycoengineering of therapeutic glycoproteins: in vitro galactosylation and sialylation of glycoproteins with terminal N-acetylglucosamine and galactose residues. , 2001, Biochemistry.

[33]  R B Freedman,et al.  Metabolic control of recombinant protein N-glycan processing in NS0 and CHO cells. , 2001, Biotechnology and bioengineering.

[34]  C. Hoy,et al.  Multiple cell culture factors can affect the glycosylation of Asn-184 in CHO-produced tissue-type plasminogen activator. , 2000, Biotechnology and bioengineering.

[35]  Gregory Stephanopoulos,et al.  Metabolic effects on recombinant interferon-gamma glycosylation in continuous culture of Chinese hamster ovary cells , 2000, IBM J. Res. Dev..

[36]  T Etcheverry,et al.  Performance of small-scale CHO perfusion cultures using an acoustic cell filtration device for cell retention: characterization of separation efficiency and impact of perfusion on product quality. , 2000, Biotechnology and bioengineering.

[37]  J. Piret,et al.  Limitations to the amplification and stability of human tissue-type plasminogen activator expression by Chinese hamster ovary cells. , 2000, Biotechnology and bioengineering.

[38]  H J Cruz,et al.  Metabolically optimised BHK cell fed-batch cultures. , 2000, Journal of biotechnology.

[39]  M. Butler,et al.  Effects of ammonia on CHO cell growth, erythropoietin production, and glycosylation. , 2000, Biotechnology and bioengineering.

[40]  T. Raju,et al.  Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. , 2000, Glycobiology.

[41]  Z. Wen,et al.  A novel perfusion system for animal cell cultures by two step sequential sedimentation. , 2000, Journal of biotechnology.

[42]  M Al-Rubeai,et al.  Influence of bcl-2 on cell death during the cultivation of a Chinese hamster ovary cell line expressing a chimeric antibody. , 2000, Biotechnology and bioengineering.

[43]  M. Betenbaugh,et al.  Part II. Overexpression of bcl-2 family members enhances survival of mammalian cells in response to various culture insults. , 2000, Biotechnology and bioengineering.

[44]  A. Kamen,et al.  Understanding factors that limit the productivity of suspension-based perfusion cultures operated at high medium renewal rates. , 2000, Biotechnology and bioengineering.

[45]  H. Katinger,et al.  Efficient selection of high-producing subclones during gene amplification of recombinant Chinese hamster ovary cells by flow cytometry and cell sorting. , 2000, Biotechnology and bioengineering.

[46]  S. Gorfien,et al.  Growth of NS0 Cells in Protein‐Free, Chemically Defined Medium , 2000, Biotechnology progress.

[47]  P. Gray,et al.  Insulin‐Like Growth Factor‐I and Transferrin Mediate Growth and Survival of Chinese Hamster Ovary Cells , 2000, Biotechnology progress.

[48]  M. Fussenegger,et al.  The Growth Factor Inhibitor Suramin Reduces Apoptosis and Cell Aggregation in Protein‐Free CHO Cell Batch Cultures , 2000, Biotechnology progress.

[49]  J. Lofgren,et al.  Engineering Chinese hamster ovary cells to maximize sialic acid content of recombinant glycoproteins , 1999, Nature Biotechnology.

[50]  M. Fussenegger,et al.  Serum protects protein-free competent Chinese hamster ovary cells against apoptosis induced by nutrient deprivation in batch culture. , 1999, Biotechnology and bioengineering.

[51]  Gregory Stephanopoulos,et al.  Metabolic effects on recombinant interferon‐γ glycosylation in continuous culture of Chinese hamster ovary cells , 1999 .

[52]  James E. Bailey,et al.  Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity , 1999, Nature Biotechnology.

[53]  G. M. Lee,et al.  Clonal variability within dihydrofolate reductase-mediated gene amplified Chinese hamster ovary cells: stability in the absence of selective pressure. , 1998, Biotechnology and bioengineering.

[54]  R. Knop,et al.  Ammonia inhibits neural cell adhesion molecule polysialylation in Chinese hamster ovary and small cell lung cancer cells , 1998, Journal of cellular physiology.

[55]  J. Dennis,et al.  The extent of polylactosamine glycosylation of MDCK LAMP-2 is determined by its Golgi residence time. , 1998, Glycobiology.

[56]  M. Butler,et al.  Dissolved oxygen concentration in serum-free continuous culture affects N-linked glycosylation of a monoclonal antibody. , 1998, Journal of biotechnology.

[57]  L Xie,et al.  Integrated approaches to the design of media and feeding strategies for fed-batch cultures of animal cells. , 1997, Trends in biotechnology.

[58]  M. Butler.  Animal Cell Culture and Technology , 1997 .

[59]  Nigel Jenkins,et al.  Getting the glycosylation right: Implications for the biotechnology industry , 1996, Nature Biotechnology.

[60]  C. Crowley,et al.  High-level production of recombinant proteins in CHO cells using a dicistronic DHFR intron expression vector. , 1996, Nucleic acids research.

[61]  T. Bibila,et al.  In Pursuit of the Optimal Fed‐Batch Process for Monoclonal Antibody Production , 1995, Biotechnology progress.

[62]  C. Goochee,et al.  The effect of cell-culture conditions on the oligosaccharide structures of secreted glycoproteins. , 1994, Current opinion in biotechnology.

[63]  N Jenkins,et al.  Glycosylation of recombinant proteins: problems and prospects. , 1994, Enzyme and microbial technology.

[64]  Eleftherios T. Papoutsakis,et al.  Culture pH Affects Expression Rates and Glycosylation of Recombinant Mouse Placental Lactogen Proteins by Chinese Hamster Ovary (CHO) Cells , 1993, Bio/Technology.

[65]  A. Bull,et al.  Glucose‐limited chemostat culture of chinese hamster ovary cells producing recombinant human interferon‐γ , 1992, Biotechnology and bioengineering.

[66]  D. King,et al.  High-Level Expression of a Recombinant Antibody from Myeloma Cells Using a Glutamine Synthetase Gene as an Amplifiable Selectable Marker , 1992, Bio/Technology.

[67]  B. Weintraub,et al.  Biological activity and metabolic clearance of a recombinant human thyrotropin produced in Chinese hamster ovary cells. , 1991, Endocrinology.

[68]  K. Gull,et al.  Recombinant human interferon-gamma. Differences in glycosylation and proteolytic processing lead to heterogeneity in batch culture. , 1990, The Biochemical journal.

[69]  M. Butler,et al.  Nutritional aspects of the growth of animal cells in culture , 1989 .

[70]  J. Vliegenthart,et al.  Clonal analysis of the glycosylation of immunoglobulin G secreted by murine hybridomas. , 1989, Biochemistry.

[71]  W. Thilly,et al.  High yields from microcarrier cultures by medium perfusion. , 1983, Journal of cell science.

[72]  R. Schimke,et al.  Expression of abbreviated mouse dihydrofolate reductase genes in cultured hamster cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[73]  A. Pavlou.  Marketspace: Trends in biotherapeutics , 1969 .